47 research outputs found
Early signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis
The objective of the study β identify early preclinical signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis.Material and methods. We examined 142 people with verified rheumatic diseases. All patients were divided into 2 groups. The first group consisted of patients with rheumatoid arthritis β 95 people. The second group β patients with ankylosing spondylitis β 47 people. The control group included 70 practically healthy individuals. In addition to standard diagnostic tests, all patients underwent tissue dopplerography of the heart using the GE Vivid E9 ultrasound device using the two-dimensional deformation technique (speckle tracking) to assess the deformation and rate of myocardial deformation, as well as determining the level of matrix metalloproteinase-9 in the blood serum.Results. Among patients with rheumatoid arthritis, diastolic dysfunction of both the left ventricle and both ventricles was more common than in the control group. The same pattern was observed in the group with ankylosing spondylitis. The calculation of the relative risk showed that the presence of rheumatoid arthritis in 4,42 times increases the risk of diastolic dysfunction of the left ventricle in comparison with practically healthy people (CI 1,6β12,2). In individuals with rheumatoid arthritis also results in a deterioration of systolic function of both ventricles. The level of matrix metalloproteinase metalloproteinase-9 was highest and most often increased in patients with ankylosing spondylitis. Among patients with rheumatoid arthritis, the average level of metalloproteinase-9 was low, but the incidence was higher than in the control group. The obtained results indicate that in these rheumatic diseases there is a marked degradation of the extracellular matrix components.Conclusion. Patients with rheumatoid arthritis and ankylosing spondylitis are characterized by a deterioration in the diastolic function of the left ventricle or both ventricles simultaneously, which is accompanied by an increase in the level of metalloproteinase-9
Evaluation of Small Intestinal Permeability in Patients with Overlap Syndrome (Autoimmune Hepatitis/Primary Biliary Cholangitis)
Πim: to evaluate the state of small intestine permeability by the βdouble sugar testβ in patients with overlap syndrome (autoimmune hepatitis / primary biliary cholangitis (AIH / PBC)).Materials and methods. Prospectively, 56 people were included in the study. Of these, 26 were diagnosed with AIH/PBC, 30 were in the control group. The diagnosis was made in accordance with the current recommendations. The average age of patients was 49.7 Β± 13.8 years, healthy volunteers β 48.6 Β± 9.2 years. The determination of the permeability of the small intestine was carried out by a βdouble sugar testβ (the ratio of lactulose/mannitol in urine), using the method of high-performance liquid chromatography β mass spectrometry.Results. In patients with AIH/PBC, an increase in intestinal permeability was found β 0.20 [0.09; 0.30] (p < 0.001) compared with the control group 0.01 [0.01; 0.02]. We divided patients at the stage of liver damage. An increased small intestinal permeability was revealed: hepatitis stage β 0.19 [0.13; 0.30] (p < 0.001), liver cirrhosis stage β 0.18 [0.09; 0.30] (p < 0.05) compared with the control group. In the early stages of disease (1 month from the onset of the disease) had an increased lactulose/mannitol ratio β 0.13 [0.05; 0.26] (p < 0.001) compared to the control group. In the presence of portal hypertension (PH), small intestinal permeability was increased β 0.18 [0.09; 0.30] (p < 0.001) compared with the control group.Conclusions. An increase in small bowel permeability was found in patients with overlapping syndrome. All patients had increased intestinal permeability (regardless of the presence of extrahepatic manifestations)
Course of COVID-19 in Patients with Inflammatory Bowel Disease: Regional Experience
Aim: to study the course of COVID-19 in patients with inflammatory bowel diseases (IBD) using the example of the region of the Republic of Tatarstan.Material and methods. The study included 101 patients diagnosed with IBD and COVID-19, who were observed in two infectious diseases hospitals in Kazan (Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan and City Clinical Hospital No. 7) and on an outpatient basis from April 2020 to March 2022. All patients underwent physical examination, laboratory and instrumental diagnostic methods, including a PCR test for SARSCoV-2. Chest computed tomography was performed in patients with clinical signs of moderate to severe COVID-19.Results. Ulcerative colitis (UC) was diagnosed in 60 (59.4 %) patients, Crohn's disease (CD) β in 41 (40.6 %) patients. The mean age of the patients was 41.0 Β± 14.7 years, of which 59 (58.4 %) were men and 42 (41.6 %) were women. A comparative analysis of patients with and without IBD and CT-verified lung disease was carried out. It was found that the development of viral pneumonia was influenced by age over 55 years (39.2 Β± 9.7 vs. 46.3 Β± 10.6, p < 0.05), increased Body Mass Index (BMI) (23.1 Β± 5.35 vs. 30.25 Β± 6.17, p < 0.05), hypertension (6 (8.3 %) vs. 8 (27.6 %), p < 0.05), diabetes mellitus (2 (2.7 %) vs. 5 (17.2 %), p < 0.05), the use of corticosteroids in the treatment of IBD (8 (11.1 %) vs. 10 (34.5 %), p < 0.05). In a comparative analysis of patients with IBD and COVID-19 from the SECURE-IBD database and own data, it was found that the average age of patients was comparable (42.7 vs 41.0). At the same time, in our group of male patients, there were slightly more people with DM, increased BMI, and an active course of IBD. The proportion of hospitalized patients was higher. In our cohort, there were fewer patients receiving biological therapy, but more patients on 5-aminosalicylic acid (5-ASA) and systemic corticosteroids. At the same time, lethal outcomes were comparable.Conclusion. In patients with IBD, the development of viral pneumonia was influenced by known risk factors for COVID-19: age over 55 years (p < 0.05, odds ratio (OR) 3.153), increased BMI (p < 0.05, OR 1.667), hypertensionΒ (p < 0.05, OR 2.724), diabetes (p < 0.05, OR 1.489), as well as the use of systemic corticosteroids (p < 0.05, OR 1.5)
COVID-19-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π°Π½Π³ΠΈΠΈΡ: ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ
The article systematizes information about various dermatological signs of a novel coronavirus infection β COVID-19. Special attention is paid to the phenomenon of COVID-19-associated angiitis. A clinical case of acroischemia associated with COVID-19 is described: on the 34th day after the onset of infection, a patient developed skin cyanosis of the distal parts of the fingers, which resolved spontaneously after a few days. The need for further research on the skin manifestations of COVID-19 and the development of an effective strategy for managing patients, as well as monitoring the condition of convalescents, is emphasized.Π ΡΡΠ°ΡΡΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°Ρ
Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ β COVID-19. ΠΡΠΎΠ±ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»Π΅Π½ΠΎ ΡΠ΅Π½ΠΎΠΌΠ΅Π½Ρ COVID-19-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π°Π½Π³ΠΈΠΈΡΠ°. ΠΠΏΠΈΡΠ°Π½ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ»ΡΡΠ°ΠΉ Π°ΠΊΡΠΎΠΈΡΠ΅ΠΌΠΈΠΈ, ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠΉ Ρ COVID-19: Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π½Π° 34-ΠΉ Π΄Π΅Π½Ρ ΠΏΠΎΡΠ»Π΅ Π΄Π΅Π±ΡΡΠ° ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠ°Π·Π²ΠΈΠ»ΡΡ ΡΠΈΠ°Π½ΠΎΠ· ΠΊΠΎΠΆΠΈ Π΄ΠΈΡΡΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠ΄Π΅Π»ΠΎΠ² ΠΏΠ°Π»ΡΡΠ΅Π² ΠΊΠΈΡΡΠ΅ΠΉ, ΡΠ°Π·ΡΠ΅ΡΠΈΠ²ΡΠΈΠΉΡΡ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎ ΡΠ΅ΡΠ΅Π· Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π΄Π½Π΅ΠΉ. ΠΠΎΠ΄ΡΠ΅ΡΠΊΠΈΠ²Π°Π΅ΡΡΡ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΊΠΎΠΆΠ½ΡΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ COVID-19 ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠΎΠ²
Π‘Π΅ΠΏΡΠ°Π»ΡΠ½ΡΠΉ ΠΏΠ°Π½Π½ΠΈΠΊΡΠ»ΠΈΡ ΠΊΠ°ΠΊ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠ΅ COVID-19: ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅
Objective: to study the clinical and laboratory features of erythema nodosum (EN) in a cohort of patients with COVID-19 referred to a rheumatological center.Patients and methods. During 2020β2021 years 21 patients (18 women and 3 men, mean age 43.2Β±11.4 years) with EN and polyarthralgia/arthritis were examined. Depending on the time of EN and articular syndrome associated with COVID-19 development, patients were divided into three groups: 1) up to 4 weeks β acute COVID (symptoms potentially associated with infection); 2) from 4 to 12 weeks β ongoing symptomatic COVID and 3) more than 12 weeks β post-COVID syndrome (persistent symptoms not associated with an alternative diagnosis). All patients underwent a comprehensive clinical, laboratory and instrumental examination, including ultrasound of the joints and chest computed tomography (CT), as well as pathomorphological examination of skin and subcutaneous adipose tissue from the site of the node (in 9 cases). Results and discussion. Based on the anamnesis data, COVID-19 in the study cohort had mild (in 13 patients) and moderate (in 8) severity. Two patients (21 years old and 23 years old) with mild severity of the disease noted red painful (45 mm on the visual analogue scale of pain) nodes on the legs and polyarthralgia for the first time on the 2nd β 3rd day from respiratory symptoms onset. In 9 (52.3%) patients, mainly with a mild course, similar skin changes were detected 24.5Β±7.6 days after active COVID-19 relieve, i.e. during the period of ongoing symptomatic COVID. In 8 (38%) patients, including 6 with moderate severity of the disease, the appearance of nodes was noted after 85.6Β±12.3 days, which corresponded to the post-COVID syndrome.At the time of examination, complaints of skin rashes and joint pain were reported in 100 and 71.4% of patients, respectively. 67% of patients had shortness of breath, weakness, cough, sweating and myalgia. Subfebrile fever had 5 (24%) patients, mainly with ongoing symptomatic COVID (3 patients). In the overwhelming majority of cases (86%), EN was located on the anterior and lateral surfaces of shins, less often on the posterior and medial surfaces. It is noteworthy that the affection of more than 50% of the surface of the lower and upper extremities was associated with the number of nodes (p<0.02), the level of CRP (p<0.03) and the presence of post-COVID syndrome (p<0.2). Fifteen (71.4%) patients had arthralgias, mainly of ankle (80%) and knee (53.3%) joints.Laboratory abnormalities included: median ESR was 34 [12; 49] mm/h, CRP level β 9 [2; 32] mg/l. The results of the polymerase chain reaction for SARS-CoV-2 were negative in all patients. In 100% of cases IgG antibodies to SARS-CoV-2 were detected and in 52.3% β IgM antibodies. On chest CT 5% lung affection was detected in 43% of patients, 5β25% lesion in 57.1% of patients, 8 (38%) of whom were with post-COVID syndrome. Pathomorphological examination of the nodes showed signs of septal panniculitis.Conclusion. When EN, associated with SARS-CoV-2 appears it is important to suspect a post-infectious manifestation in time, based on the clinical picture of the disease and to determine the scope of further examination and adequate treatment.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ·Π»ΠΎΠ²Π°ΡΠΎΠΉ ΡΡΠΈΡΠ΅ΠΌΡ (Π£Π) Π² ΠΊΠΎΠ³ΠΎΡΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
COVID-19, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΡ
Π² ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ΅Π½ΡΡ.ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 2020β2021 Π³Π³. ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ 21 ΠΏΠ°ΡΠΈΠ΅Π½Ρ (18 ΠΆΠ΅Π½ΡΠΈΠ½ ΠΈ 3 ΠΌΡΠΆΡΠΈΠ½Ρ, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 43,2Β±11,4 Π³ΠΎΠ΄Π°) Ρ Π£Π ΠΈ ΠΏΠΎΠ»ΠΈΠ°ΡΡΡΠ°Π»Π³ΠΈΡΠΌΠΈ/Π°ΡΡΡΠΈΡΠ°ΠΌΠΈ. Π Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π£Π ΠΈ ΡΡΡΡΠ°Π²Π½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ COVID-19, ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° ΡΡΠΈ Π³ΡΡΠΏΠΏΡ: 1) Π΄ΠΎ 4 Π½Π΅Π΄ β ΠΎΡΡΡΡΠΉ COVID (ΡΠΈΠΌΠΏΡΠΎΠΌΡ, ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΠ²ΡΠ·Π°Π½Π½ΡΠ΅ Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ); 2) ΠΎΡ 4 Π΄ΠΎ 12 Π½Π΅Π΄ β ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°ΡΡΠΈΠΉΡΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ COVID ΠΈ 3) Π±ΠΎΠ»Π΅Π΅ 12 Π½Π΅Π΄ β ΠΏΠΎΡΡΠΊΠΎΠ²ΠΈΠ΄Π½ΡΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ (ΡΠΎΡ
ΡΠ°Π½ΡΡΡΠΈΠ΅ΡΡ ΡΡΠΎΠΉΠΊΠΈΠ΅ ΡΠΈΠΌΠΏΡΠΎΠΌΡ, Π½Π΅ ΡΠ²ΡΠ·Π°Π½Π½ΡΠ΅ Ρ Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ). ΠΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΈ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, Π²ΠΊΠ»ΡΡΠ°Ρ Π£ΠΠ ΡΡΡΡΠ°Π²ΠΎΠ² ΠΈ ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΡΡ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΡ (ΠΠ’) ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΡΡΠ΄Π½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΊΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ (Π² 9 ΡΠ»ΡΡΠ°ΡΡ
) ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² ΠΊΠΎΠΆΠΈ ΠΈ ΠΏΠΎΠ΄ΠΊΠΎΠΆΠ½ΠΎΠΉ ΠΆΠΈΡΠΎΠ²ΠΎΠΉ ΠΊΠ»Π΅ΡΡΠ°ΡΠΊΠΈ ΠΈΠ· ΠΎΠ±Π»Π°ΡΡΠΈ ΡΠ·Π»Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π°Π½Π½ΡΡ
Π°Π½Π°ΠΌΠ½Π΅Π·Π° Π‘OVID-19 Π² ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠΉ ΠΊΠΎΠ³ΠΎΡΡΠ΅ ΠΈΠΌΠ΅Π» Π»Π΅Π³ΠΊΡΡ (Ρ 13 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²) ΠΈ ΡΡΠ΅Π΄Π½ΡΡ (Ρ 8) ΡΡΠ΅ΠΏΠ΅Π½Ρ ΡΡΠΆΠ΅ΡΡΠΈ. ΠΠ²ΠΎΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
(21 Π³ΠΎΠ΄Π° ΠΈ 23 Π»Π΅Ρ) Ρ Π»Π΅Π³ΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΡΠΆΠ΅ΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π½Π° 2-Π΅ β 3-ΠΈ ΡΡΡΠΊΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΌΠΏΡΠΎΠΌΠ° Π²ΠΏΠ΅ΡΠ²ΡΠ΅ ΠΎΡΠΌΠ΅ΡΠΈΠ»ΠΈ ΠΊΡΠ°ΡΠ½ΡΠ΅ Π±ΠΎΠ»Π΅Π·Π½Π΅Π½Π½ΡΠ΅ (45 ΠΌΠΌ ΠΏΠΎ Π²ΠΈΠ·ΡΠ°Π»ΡΠ½ΠΎΠΉ Π°Π½Π°Π»ΠΎΠ³ΠΎΠ²ΠΎΠΉ ΡΠΊΠ°Π»Π΅) ΡΠ·Π»Ρ Π½Π° Π³ΠΎΠ»Π΅Π½ΡΡ
ΠΈ ΠΏΠΎΠ»ΠΈΠ°ΡΡΡΠ°Π»Π³ΠΈΠΈ. Π£ 9 (52,3%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Ρ Π»Π΅Π³ΠΊΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ, Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠΎΠΆΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ ΡΠ΅ΡΠ΅Π· 24,5Β±7,6 ΡΡΡ ΠΏΠΎΡΠ»Π΅ ΠΊΡΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π‘OVID-19, Ρ. Π΅. Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°ΡΡΠ΅Π³ΠΎΡΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ COVID. Π£ 8 (38%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Ρ 6 ΡΠΎ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΡΠΆΠ΅ΡΡΠΈ Π±ΠΎΠ»Π΅Π·Π½ΠΈ, ΡΠ·Π»Ρ Π²ΠΎΠ·Π½ΠΈΠΊΠ°Π»ΠΈ ΡΠ΅ΡΠ΅Π· 85,6Β±12,3 ΡΡΡ, ΡΡΠΎ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΎΠ²Π°Π»ΠΎ ΠΏΠΎΡΡΠΊΠΎΠ²ΠΈΠ΄Π½ΠΎΠΌΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ.ΠΠ° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΎΡΠΌΠΎΡΡΠ° ΠΆΠ°Π»ΠΎΠ±Ρ Π½Π° ΠΊΠΎΠΆΠ½ΡΠ΅ Π²ΡΡΡΠΏΠ°Π½ΠΈΡ ΠΈ Π±ΠΎΠ»Ρ Π² ΡΡΡΡΠ°Π²Π°Ρ
ΠΏΡΠ΅Π΄ΡΡΠ²Π»ΡΠ»ΠΈ 100 ΠΈ 71,4% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ΄ΡΡΠΊΠ°, ΡΠ»Π°Π±ΠΎΡΡΡ, ΠΊΠ°ΡΠ΅Π»Ρ, ΠΏΠΎΡΠ»ΠΈΠ²ΠΎΡΡΡ ΠΈ ΠΌΠΈΠ°Π»Π³ΠΈΠΈ Π±Π΅ΡΠΏΠΎΠΊΠΎΠΈΠ»ΠΈ 67% Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΡ ΡΠ΅Π»Π° Π΄ΠΎ ΡΡΠ±ΡΠ΅Π±ΡΠΈΠ»ΡΠ½ΠΎΠΉ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ Ρ 5 (24%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΡΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°ΡΡΠ΅ΠΌΡΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ COVID (3 Π±ΠΎΠ»ΡΠ½ΡΡ
). Π ΠΏΠΎΠ΄Π°Π²Π»ΡΡΡΠ΅ΠΌ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² (86%) Π£Π ΡΠ°ΡΠΏΠΎΠ»Π°Π³Π°Π»Π°ΡΡ Π½Π° ΠΏΠ΅ΡΠ΅Π΄Π½Π΅ΠΉ ΠΈ Π»Π°ΡΠ΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΡΡ
Π³ΠΎΠ»Π΅Π½Π΅ΠΉ, ΡΠ΅ΠΆΠ΅ β Π½Π° Π·Π°Π΄Π½Π΅ΠΉ ΠΈ ΠΌΠ΅Π΄ΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΡΡ
. ΠΡΠΈΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΠ½ΠΎ, ΡΡΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ Π±ΠΎΠ»Π΅Π΅ 50% ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ Π½ΠΈΠΆΠ½ΠΈΡ
ΠΈ Π²Π΅ΡΡ
Π½ΠΈΡ
ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ΅ΠΉ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π»ΠΎΡΡ Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎΠΌ ΡΠ·Π»ΠΎΠ² (Ρ<0,02), ΡΡΠΎΠ²Π½Π΅ΠΌ Π‘Π Π (Ρ<0,03) ΠΈ ΠΏΠΎΡΡΠΊΠΎΠ²ΠΈΠ΄Π½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ (Ρ<0,2). Π£ 15 (71,4%) Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈΠΌΠ΅Π»ΠΈΡΡ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ Π°ΡΡΡΠ°Π»Π³ΠΈΠΉ, ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π³ΠΎΠ»Π΅Π½ΠΎΡΡΠΎΠΏΠ½ΡΡ
(80%) ΠΈ ΠΊΠΎΠ»Π΅Π½Π½ΡΡ
(53,3%) ΡΡΡΡΠ°Π²ΠΎΠ².ΠΡΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠ΅Π΄ΠΈΠ°Π½Π° Π‘ΠΠ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 34 [12; 49] ΠΌΠΌ/Ρ, ΡΡΠΎΠ²Π½Ρ Π‘Π Π β 9 [2; 32] ΠΌΠ³/Π». Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° SARS-CoV-2 Π±ΡΠ»ΠΈ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΡΠΌΠΈ Ρ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π 100% ΡΠ»ΡΡΠ°Π΅Π² Π²ΡΡΠ²Π»Π΅Π½Ρ Π°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΈ Π² 52,3% β IgM ΠΊ Π²ΠΈΡΡΡΡ SARS-CoV-2. ΠΡΠΈ ΠΠ’ ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΡΡΠ΄Π½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΊΠΈ 5% ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ Ρ 43% Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΎΡ 5 Π΄ΠΎ 25% β Ρ 57,1%, ΠΈΠ· Π½ΠΈΡ
Ρ 8 (38%) Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΠΎΡΡΠΊΠΎΠ²ΠΈΠ΄Π½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ. ΠΡΠΈ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ·Π»ΠΎΠ² ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΡΠ΅ΠΏΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΠ°Π½Π½ΠΈΠΊΡΠ»ΠΈΡΠ°.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π£Π, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Ρ SARS-CoV-2, Π²Π°ΠΆΠ½ΠΎ Π²ΠΎΠ²ΡΠ΅ΠΌΡ Π·Π°ΠΏΠΎΠ΄ΠΎΠ·ΡΠΈΡΡ ΠΏΠΎΡΡΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΎΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠ΅ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΠΎΠ±ΡΠ΅ΠΌ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅
L.L. Fofanof: 140th anniversary of his birth. Contribution to science
The article is dedicated to Professor L.L. Fofanofβs scientific activity. He headed the faculty therapeutic clinic of Kazan Imperial University in 1915-1920. Being a student L.L. Fofanov was interested in pathological anatomy and physiology. His dissertation Β«To physiology of n. depressorisΒ» was dedicated to studying the vasomotor center. During his visit in Germany he worked a lot. In Charite together with Professor His he studied gout and its treatment with Radium emanation. In Halle clinic under Professor Schmidtβs supervision he studied assimilation of starch in normal and pathological digestion. L.L. Fofanov also made a contribution to tuberculosis treatment: with professor V.F. Orlovskiy he studied treatment of tuberculosis with simulated pneumothorax. In his research professor L.L. Fofanov paid great attention to the issues of pathogenesis and pathogenetic substantiation of the clinical manifestation and treatment. During the World War I and Civil War he fought against typhus epidemies: he saw patients, gave lectures, studied the features of myocardial involvement. He died in 1920 from typhus
Thirteen-Year Follow-Up of a Patient with Liver Cirrhosis Resulting from the Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis: Severe COVID-19 and Liver Transplantation
Aim: to present the difficulties of long-term management of a patient with liver cirrhosis in the outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis) who suffered from severe COVID-19 infection.Key points. The diagnosis of liver cirrhosis as an outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis) was established at the patientβs age of 33 years. At the age of 40, the patient became pregnant for the first time, the pregnancy proceeded well, and a cesarean section was performed at 36 weeks. At the age of 45, the patient suffered a severe new coronavirus infection, followed by decompensation of liver cirrhosis, which required liver transplantation 4 months after COVID-19, followed by a favorable postoperative course.Conclusion. This clinical case demonstrates the successful onset and outcome of pregnancy in a patient with liver cirrhosis in the outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis). The pronounced activity of the disease after severe new coronavirus infection required liver transplantation with successful outcome
To the 50th anniversary of hematology service of the Republic of Tatarstan
The article presents an overview of the development of hematology service in the Republic of Tatarstan. The well-known scientist Nikolay Konstantinovich Goryaev (1875-1943), who worked in Kazan for a long time, began to develop this direction and after passing an internship in Germany proposed an improved device for calculating the blood elements known throughout the world. Adherents of Professor Goryaev continued research in the field of hematology, a blood transfusion station was organized. Professor S.I. Sherman proposed new methods of diagnosis and treatment of B12 deficiency anemia. Professor Sh.I. Ratner studied the changes in the blood picture in diseases of the abdominal cavity. The first 15 specialized hematological beds were opened in 1968 in the hospital named βOld Clinicβ. The physician who treated such patients was Rakhil Sholomovna Dashevskaya, PhD. At present, hematology service is provided by three hospitals in Kazan, hematological and therapeutical beds in Naberezhnye Chelny and Nizhnekamsk, outpatient hematology service in Zelenodolsk. In recent years, the introduction of stem cell therapy has begun, and modern combined methods of chemotherapy have been introduced